Apoptosis-modulating drugs for improved cancer therapy (Q38005914)

26 August 2017

Apoptosis-modulating drugs for improved cancer therapy (English)

1 reference

26 August 2017

1 reference

M Ocker

1

1 reference

PubMed ID

22538523

26 August 2017

M Höpfner

series ordinal

2

1 reference

26 August 2017

24 April 2012

1 reference

European Surgical Research

26 August 2017

1 reference

26 August 2017

48

1 reference

26 August 2017

3

1 reference

26 August 2017

111-120

1 reference

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

26 August 2017

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail?

21 January 2018

1 reference

Molecular mechanisms of drug resistance

21 January 2018

1 reference

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials

21 January 2018

1 reference

Cetuximab in the treatment of patients with colorectal cancer

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

Understanding autophagy in cell death control.

21 January 2018

1 reference

The roles of therapy-induced autophagy and necrosis in cancer treatment

21 January 2018

1 reference

Eaten alive: a history of macroautophagy

21 January 2018

1 reference

Death through a tragedy: mitotic catastrophe

21 January 2018

1 reference

Cell death by mitotic catastrophe: a molecular definition

21 January 2018

1 reference

Molecular steps of death receptor and mitochondrial pathways of apoptosis

21 January 2018

1 reference

Overview of cell death signaling pathways

21 January 2018

1 reference

Corpse clearance defines the meaning of cell death

21 January 2018

1 reference

Tumor necrosis factor signaling.

21 January 2018

1 reference

Signal transduction by tumor necrosis factor and its relatives

21 January 2018

1 reference

Targeting the extrinsic apoptosis signaling pathway for cancer therapy

21 January 2018

1 reference

The CD95(APO-1/Fas) DISC and beyond

21 January 2018

1 reference

Inhibition of death receptor signals by cellular FLIP

21 January 2018

1 reference

To kill a tumor cell: the potential of proapoptotic receptor agonists

21 January 2018

1 reference

The Bcl2 family: regulators of the cellular life-or-death switch

21 January 2018

1 reference

BH3-only proteins and their roles in programmed cell death

21 January 2018

1 reference

The mitochondrion in apoptosis: how Pandora's box opens

21 January 2018

1 reference

The pathophysiology of mitochondrial cell death

21 January 2018

1 reference

Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c

21 January 2018

1 reference

The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant

21 January 2018

1 reference

Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3

21 January 2018

1 reference

Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade

21 January 2018

1 reference

Structure of an apoptosome-procaspase-9 CARD complex.

21 January 2018

1 reference

BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis

21 January 2018

1 reference

BAD and Bcl-2 regulation are early events linking neuronal endoplasmic reticulum stress to mitochondria-mediated apoptosis

21 January 2018

1 reference

Organelle-specific initiation of cell death pathways

21 January 2018

1 reference

Integrating stress signals at the endoplasmic reticulum: The BCL-2 protein family rheostat.

21 January 2018

1 reference

Calcium and cell death mechanisms: a perspective from the cell death community

21 January 2018

1 reference

The unfolded protein response: from stress pathway to homeostatic regulation

21 January 2018

1 reference

Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress

21 January 2018

1 reference

ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals

21 January 2018

1 reference

Signal integration in the endoplasmic reticulum unfolded protein response

21 January 2018

1 reference

Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta

21 January 2018

1 reference

Perk is essential for translational regulation and cell survival during the unfolded protein response

21 January 2018

1 reference

Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1

21 January 2018

1 reference

The death domain superfamily in intracellular signaling of apoptosis and inflammation

21 January 2018

1 reference

Serial killers: ordering caspase activation events in apoptosis

21 January 2018

1 reference

21 January 2018

1 reference

Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis

21 January 2018

1 reference

Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death

21 January 2018

1 reference

Apoptosis generates stable fragments of human type I keratins

21 January 2018

1 reference

Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis

21 January 2018

1 reference

Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I.

21 January 2018

1 reference

Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade

21 January 2018

1 reference

Cleavage of DFF-45/ICAD by multiple caspases is essential for its function during apoptosis

21 January 2018

1 reference

Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis

21 January 2018

1 reference

Survivin and IAP proteins in cell-death mechanisms

21 January 2018

1 reference

IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer

21 January 2018

1 reference

Inhibitor of apoptosis proteins and apoptosis

21 January 2018

1 reference

Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases

21 January 2018

1 reference

21 January 2018

IAPs: guardians of RIPK1

1 reference

Death by design: apoptosis, necrosis and autophagy

21 January 2018

1 reference

Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway

21 January 2018

1 reference

Molecular mechanisms of necroptosis: an ordered cellular explosion

21 January 2018

1 reference

Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury

21 January 2018

1 reference

Inhibition of ADP/ATP exchange in receptor-interacting protein-mediated necrosis

21 January 2018

1 reference

Expansion and evolution of cell death programmes

21 January 2018

1 reference

RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts

21 January 2018

1 reference

Crystal structure of the Bcl-XL-Beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein

21 January 2018

1 reference

Regulation mechanisms and signaling pathways of autophagy

21 January 2018

1 reference

New insights into the mechanisms of macroautophagy in mammalian cells

21 January 2018

1 reference

Autophagy promotes necrosis in apoptosis-deficient cells in response to ER stress

21 January 2018

1 reference

Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes

21 January 2018

1 reference

Autophagy: dual roles in life and death?

21 January 2018

1 reference

Fenretinide induces autophagic cell death in caspase-defective breast cancer cells.

21 January 2018

1 reference

Anoikis resistance and tumor metastasis

21 January 2018

1 reference

Prognostic role of sensitive-to-apoptosis gene expression in rectal cancer

21 January 2018

1 reference

Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer

21 January 2018

1 reference

Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer

21 January 2018

1 reference

Correlation between loss of Bcl-XL expression and improved prognosis in advanced esophageal cancer treated by preoperative chemoradiotherapy

21 January 2018

1 reference

Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma

21 January 2018

1 reference

Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma.

21 January 2018

1 reference

Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy

21 January 2018

1 reference

Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.

21 January 2018

1 reference

Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma

21 January 2018

1 reference

CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme.

21 January 2018

1 reference

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

21 January 2018

1 reference

Regulation of cell death protease caspase-9 by phosphorylation

21 January 2018

1 reference

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

Ras is involved in the negative control of autophagy through the class I PI3-kinase

21 January 2018

1 reference

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

21 January 2018

1 reference

Death receptor agonists as a targeted therapy for cancer

21 January 2018

1 reference

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

21 January 2018

1 reference

A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes

21 January 2018

1 reference

Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model

21 January 2018

1 reference

Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)

21 January 2018

1 reference

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

21 January 2018

1 reference

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.

21 January 2018

1 reference

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study

21 January 2018

1 reference

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

21 January 2018

1 reference

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer

21 January 2018

1 reference

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer

21 January 2018

1 reference

The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells

21 January 2018

1 reference

Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis

21 January 2018

1 reference

Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region

21 January 2018

1 reference

Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands

21 January 2018

1 reference

Mimicking the BH3 domain to kill cancer cells

21 January 2018

1 reference

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

21 January 2018

1 reference

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer

21 January 2018

1 reference

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen

21 January 2018

1 reference

Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer

21 January 2018

1 reference

bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells

21 January 2018

1 reference

Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma

21 January 2018

1 reference

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

21 January 2018

1 reference

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

21 January 2018

1 reference

Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.

21 January 2018

1 reference

Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer

21 January 2018

1 reference

Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.

21 January 2018

1 reference

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

21 January 2018

1 reference

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

21 January 2018

1 reference

Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models

21 January 2018

1 reference

The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.

21 January 2018

1 reference

Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells

21 January 2018

1 reference

Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma

21 January 2018

1 reference

Deacetylase inhibitors - focus on non-histone targets and effects

21 January 2018

1 reference

Autophagy-A double-edged sword in oncology

21 January 2018

1 reference

The role of autophagy in cancer: therapeutic implications

21 January 2018

1 reference

Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells

21 January 2018

1 reference

Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis

21 January 2018

1 reference

Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells

21 January 2018

1 reference

Smac mimetics as new cancer therapeutics.

21 January 2018

1 reference

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

21 January 2018

1 reference

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia

21 January 2018

1 reference

Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin

21 January 2018

1 reference

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

21 January 2018

1 reference

Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000336875

1 reference

26 August 2017

1 reference

PubMed ID

22538523